Skip to content
value.today
Cerenome, Inc. logo

Cerenome, Inc.

Formerly Plus Therapeutics, Inc.

Total raised
$4 M
1 round on record
Latest round
$4 M
May 2009
First round on record
May 2009
Today
Went public
See the company page

Cerenome, Inc. is listed today as Cerenome, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Cerenome, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2026$3 MPrivate placement after listing$2 to $10 million

Cerenome, Inc.: Private sale, Sep 2026

Investors in this round

1 investor had bought by the notice of Sep 18, 2026: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $20 M offered; $17 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew H. Sims · Executive Officer · Chief Financial Officer
  • Marc H. Hedrick · Executive Officer, Director · President and Chief Executive Officer
  • An H. van Es-Johansson · Director
  • Howard H. Clowes · Director
  • Kyle A. Guse · Director
  • Richard J. Hawkins · Director · Chairman of the Board
  • Ronald A. Andrews · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The Company agreed to issue senior secured convertible notes in the aggregate original principal amount of up to $21,276,596, and each of the notes, when issued, reflects an original issue discount of 6.0%.”

Signed by Andrew Sims, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 18, 2026. Read the notice at the SEC.

equity, debt, optionsSEC
May 2009$4 MNo. 1$2 to $10 million

Cerenome, Inc.: Raise no. 1, May 2009

Investors in this round

41 investors had bought by the notice of Jun 30, 2009: 41 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $13 M offered; $9 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher J Calhoun · Executive Officer, Director
  • Marc H Hedrick · Executive Officer, Director
  • Mark E Saad · Executive Officer
  • David M Rickey · Director
  • E Carmack Holmes, MD · Director
  • Paul W Hawran · Director
  • Richard J Hawkins · Director
  • Ronald D Henriksen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The remaining $8,550,056 represents the aggregate exercise price of the common stock warrants issued as part of this offering.”

Signed by Jonathan E. Soneff, Secretary. Source: SEC Form D, newest notice filed Jun 30, 2009. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Cerenome, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2026).

    SEC Form D · Sep 2026

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Sep 2026

That is all the official record says: Cerenome, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Cerenome, Inc. are on record.

Investors#

No investor of Cerenome, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 41 investors.

Largest shareholders today

Institutions holding Cerenome, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cerenome, Inc.
NameRoleNamed in
Andrew H. SimsChief Financial OfficerSep 2026
Marc H. HedrickPresident and Chief Executive OfficerSep 2026
Christopher J CalhounExecutive officerJun 2009
Marc H HedrickExecutive officerJun 2009
Mark E SaadExecutive officerJun 2009
An H. van Es-JohanssonDirectorSep 2026
Howard H. ClowesDirectorSep 2026
Kyle A. GuseDirectorSep 2026
Marc H. HedrickPresident and Chief Executive OfficerSep 2026
Richard J. HawkinsChairman of the BoardSep 2026
Ronald A. AndrewsDirectorSep 2026
Christopher J CalhounDirectorJun 2009
David M RickeyDirectorJun 2009
E Carmack Holmes, MDDirectorJun 2009
Marc H HedrickDirectorJun 2009
Paul W HawranDirectorJun 2009
Richard J HawkinsDirectorJun 2009
Ronald D HenriksenDirectorJun 2009

About

Biopharmaceutical company.

Went public since 2011. Its SEC number is that of a company listed on a stock exchange.